lixte biotechnology holdings inc shares more than doubled in premarket trading wednesday after the company said its lead clinical compound was found in an outside animal study to make various cancers more vulnerable to immunotherapy treatment the clinicalstage drug discovery company said that researchers in taiwan found lixtes lb100 compound helped improve the success rate of anticancer immunotherapy the preclinical research was the focus of a peerreviewed article in the medical journal nature communications authored by yuting yen and colleagues the results of yen et al raise the possibility that the addition of lb100 to immunotherapy may be a simple way to convert cold into hot tumors thereby increasing the percentage of patients responsive to immunotherapy lixtes chief executive john kovach said shares in lixte biotechnology jumped 122 to 3 a share in premarket trading write to will feuer at willfeuerwsjcom